bioRxiv Preprint Server
April 9, 2024
Çağatay Demirel, Jarrod Gott, Kristoffer Appel et al.
2 citations
preprint
Lucid dreaming, a state of conscious awareness during REM sleep, is associated with specific brain activity patterns. Compared to non-lucid REM sleep, EEG sensor-level differences were few. However, source-level analysis revealed increased gamma1 power (30-36 Hz) in left-hemispheric temporal areas during lucid dreaming, potentially reflecting verbal insight processes, and in right temporo-occipital regions including the precuneus around the onset of lucid eye signaling, linked to self-referential thinking. Beta power (12-30 Hz) decreased in right central and parietal areas including the temporo-parietal junction, possibly related to conscious reality assessment. Alpha-band (8-12 Hz) functional connectivity increased, contrasting with psychedelic states and highlighting enhanced self-awareness.
Scientific Reports
July 14, 2024
Annie C. Souza, Bryan C. Souza, Arthur França et al.
1 citation
No Summary
Jornal Brasileiro de Psiquiatria
January 1, 2024
Dráulio Barros de Araújo, Tiago Arruda Sanchez, Sidarta Ribeiro
1 citation
Psychedelic substances have been used by humanity for millennia to induce non-ordinary states of consciousness, characterized by heightened sensory, emotional, and cognitive experiences, including augmented visual imagery, altered perception of space-time and reality, and profound mystical insights. Many indigenous populations worldwide developed these substances as vital components of healing. In the Amazon, shamans ancestrally used Ayahuasca, a drink made from two plants, to promote physical and psychological healing. The Navajo in North America retain the ancestral use of the peyote cactus as sacred medicine, while the Mazatecs of Mexico used psilocybin-containing mushrooms in their healing rituals.
Journal of Psychedelic Studies
June 9, 2023
Beatriz Caiuby Labate, Anna O. Ermakova, Jordan Sloshower et al.
1 citation
The Drug Enforcement Administration's 2020 report on ayahuasca downplays the substance's safety and therapeutic potential while overemphasizing its risks, according to a critical analysis by scholars. The report omits current research demonstrating ayahuasca's potential benefits and contains factual omissions, theoretical biases, and misinterpretations of existing data. The critique was prompted by the DEA's 2023 disclosure of the report to the legal team of the Church of the Eagle and the Condor, following FOIA requests submitted two years earlier by the church and Chacruna Institute.
Ponto Urbe
December 27, 2024
Beatriz Caiuby Labate, Anna O. Ermakova, Jordan Sloshower et al.
In February 2023, the U.S. Drug Enforcement Administration (DEA) released a 2020 report titled 'Ayahuasca: Risks to Public Health and Safety' to the legal team of the Church of the Eagle and the Condor, following Freedom of Information Act requests. This article challenges several claims in the DEA report, highlighting factual omissions, theoretical biases, and misinterpretations of existing data. The authors argue that the report minimizes ayahuasca's safety profile and therapeutic potential while overemphasizing risks, and fails to include current research demonstrating its potential benefits.
bioRxiv (Cold Spring Harbor Laboratory)
June 5, 2023
Annie Da Costa Souza, Bryan Da Costa Souza, Arthur S. C. França et al.
preprint
The psychedelic 5-MeO-DMT increases delta power and decreases theta power in the hippocampus of freely moving rats, effects not explained by changes in locomotion. It also dose-dependently reduces slow and mid gamma power and theta phase modulation. The overall spectral profile of awake behavior after 5-MeO-DMT resembles electrophysiological states seen during slow-wave sleep and REM sleep. These findings suggest that classical psychedelics may integrate waking behaviors with sleep-like neural activity patterns.
bioRxiv (Cold Spring Harbor Laboratory)
February 13, 2017
Vanja Dakic, Juliana Nascimento, Rafaela Sartore et al.
preprint
5-MeO-DMT, a hallucinogenic molecule found in traditional Amerindian medicine, alters the proteome of human cerebral organoids. Of 6,728 identified proteins, 934 were differentially expressed after treatment. Systems biology analyses indicate anti-inflammatory effects and modulation of proteins linked to long-term potentiation, dendritic spine formation, cellular protrusion, microtubule dynamics, and cytoskeletal reorganization. These findings provide mechanistic insights into the neuropsychological changes associated with dimethyltryptamine ingestion.